Emergent Biosolutions Slide After Widening 4Q Loss, Logging Lower Revenue

Dow Jones

Feb 27

By Connor Hart

Shares of Emergent Biosolutions fell after the company widened its loss and logged lower revenue during the fourth quarter.

The stock sank 23%, to $8.58, in premarket trading Friday. Through Thursday's close, shares are up 48% over the past year.

The company after Thursday's closing bell posted a loss of $54.6 million, or $1.04 a share, compared with a loss of $31.3 million, or 58 cents a share, a year earlier.

Stripping out one-time items, Emergent reported a loss of 43 cents a share.

Revenue fell to $148.7 million, from $194.7 million in the same quarter last year.

Chief Executive Joe Papa said the company made progress executing on its multi-year turnaround strategy last year, citing improved operating margins, increased cash flow and lower leverage.

Looking forward, the company in 2026 aims to expand its international operations, pursue growth opportunities and remain disciplined on operational efficiencies, he added.

For the current quarter, Emergent guided for revenue of $135 million to $155 million.

For the year, the company forecast a net loss between $10 million and $30 million, or earnings of $25 million to $45 million on an adjusted basis. Revenue is projected to come in between $720 million and $760 million, the midpoint of which is below the $742.9 million in revenue the company posted last year.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

February 27, 2026 06:51 ET (11:51 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2614583016"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614583016\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614583016?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 19:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614583016","market":"hk","top_or_hot":-1,"title":"Emergent Biosolutions Slide After Widening 4Q Loss, Logging Lower Revenue","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/EBS\">Emergent Biosolutions</a> fell after the company widened its loss and logged lower revenue during the fourth quarter. \n</p>\n<p>\n  The stock sank 23%, to $8.58, in premarket trading Friday. Through Thursday's close, shares are up 48% over the past year. \n</p>\n<p>\n  The company after Thursday's closing bell posted a loss of $54.6 million, or $1.04 a share, compared with a loss of $31.3 million, or 58 cents a share, a year earlier. \n</p>\n<p>\n  Stripping out one-time items, Emergent reported a loss of 43 cents a share. \n</p>\n<p>\n  Revenue fell to $148.7 million, from $194.7 million in the same quarter last year. \n</p>\n<p>\n  Chief Executive Joe Papa said the company made progress executing on its multi-year turnaround strategy last year, citing improved operating margins, increased cash flow and lower leverage. \n</p>\n<p>\n  Looking forward, the company in 2026 aims to expand its international operations, pursue growth opportunities and remain disciplined on operational efficiencies, he added. \n</p>\n<p>\n  For the current quarter, Emergent guided for revenue of $135 million to $155 million. \n</p>\n<p>\n  For the year, the company forecast a net loss between $10 million and $30 million, or earnings of $25 million to $45 million on an adjusted basis. Revenue is projected to come in between $720 million and $760 million, the midpoint of which is below the $742.9 million in revenue the company posted last year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 27, 2026 06:51 ET (11:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Emergent Biosolutions Slide After Widening 4Q Loss, Logging Lower Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEmergent Biosolutions Slide After Widening 4Q Loss, Logging Lower Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-27 19:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/EBS\">Emergent Biosolutions</a> fell after the company widened its loss and logged lower revenue during the fourth quarter. \n</p>\n<p>\n  The stock sank 23%, to $8.58, in premarket trading Friday. Through Thursday's close, shares are up 48% over the past year. \n</p>\n<p>\n  The company after Thursday's closing bell posted a loss of $54.6 million, or $1.04 a share, compared with a loss of $31.3 million, or 58 cents a share, a year earlier. \n</p>\n<p>\n  Stripping out one-time items, Emergent reported a loss of 43 cents a share. \n</p>\n<p>\n  Revenue fell to $148.7 million, from $194.7 million in the same quarter last year. \n</p>\n<p>\n  Chief Executive Joe Papa said the company made progress executing on its multi-year turnaround strategy last year, citing improved operating margins, increased cash flow and lower leverage. \n</p>\n<p>\n  Looking forward, the company in 2026 aims to expand its international operations, pursue growth opportunities and remain disciplined on operational efficiencies, he added. \n</p>\n<p>\n  For the current quarter, Emergent guided for revenue of $135 million to $155 million. \n</p>\n<p>\n  For the year, the company forecast a net loss between $10 million and $30 million, or earnings of $25 million to $45 million on an adjusted basis. Revenue is projected to come in between $720 million and $760 million, the midpoint of which is below the $742.9 million in revenue the company posted last year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 27, 2026 06:51 ET (11:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EBS","symbol_name":"Emergent Biosolutions","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2614583016","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614583016","pubTimestamp":1772193060,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Emergent Biosolutions fell after the company widened its loss and logged lower revenue during the fourth quarter.The stock sank 23%, to $8.58, in premarket trading Friday. Through Thursday's close, shares are up 48% over the past year.The company after Thursday's closing bell posted a loss of $54.6 million, or $1.04 a share, compared with a loss of $31.3 million, or 58 cents a share, a year earlier.Stripping out one-time items, Emergent reported a loss of 43 cents a share.Revenue fell to $148.7 million, from $194.7 million in the same quarter last year.Chief Executive Joe Papa said the company made progress executing on its multi-year turnaround strategy last year, citing improved operating margins, increased cash flow and lower leverage.For the year, the company forecast a net loss between $10 million and $30 million, or earnings of $25 million to $45 million on an adjusted basis. Revenue is projected to come in between $720 million and $760 million, the midpoint of which is","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EBS":"Emergent Biosolutions","BK4139":"生物科技","BK4583":"猴痘概念"},"translate_title":"Emergent Biosolutions在第四季度亏损扩大、收入下降后下滑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EBS":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Emergent Biosolutions fell after the company widened its loss and logged lower revenue during the fourth quarter. \n\n\n  The stock sank 23%, to $8.58, in premarket trading Friday. Through Thursday's close, shares are up 48% over the past year. \n\n\n  The company after Thursday's closing bell posted a loss of $54.6 million, or $1.04 a share, compared with a loss of $31.3 million, or 58 cents a share, a year earlier. \n\n\n  Stripping out one-time items, Emergent reported a loss of 43 cents a share. \n\n\n  Revenue fell to $148.7 million, from $194.7 million in the same quarter last year. \n\n\n  Chief Executive Joe Papa said the company made progress executing on its multi-year turnaround strategy last year, citing improved operating margins, increased cash flow and lower leverage. \n\n\n  Looking forward, the company in 2026 aims to expand its international operations, pursue growth opportunities and remain disciplined on operational efficiencies, he added. \n\n\n  For the current quarter, Emergent guided for revenue of $135 million to $155 million. \n\n\n  For the year, the company forecast a net loss between $10 million and $30 million, or earnings of $25 million to $45 million on an adjusted basis. Revenue is projected to come in between $720 million and $760 million, the midpoint of which is below the $742.9 million in revenue the company posted last year. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 27, 2026 06:51 ET (11:51 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}